CAMP4 THERAPEUTICS CORPORATION

CAMP • US

$5.44+$0.94 (20.89%)

LABEL.WIIM.TITLE.TODAY

CAMP4 Therapeutics shares are trading higher afte...

Estimate

EPS

-2.31

Beta

0.034

Growth

Revenue, YoY

18.84%

Net income, YoY

-166.39%

FCF, YoY

-23.9%

Forecast

EPS (FWD)

-0.795

About the company

Ticker

CAMP

ISIN

US1281261099

Country

United States of America

Sector (GICS)

Information Technology

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

What sector does CAMP4 THERAPEUTICS CORPORATION (CAMP) operate in?

CAMP4 THERAPEUTICS CORPORATION belongs to the Information Technology sector and operates in the Biotechnology industry.

What is CAMP4 THERAPEUTICS CORPORATION (CAMP) current stock price?

As of the latest data, CAMP4 THERAPEUTICS CORPORATION stock price is $5.44, with a previous close of $4.50. CAMP4 THERAPEUTICS CORPORATION gained $0.94 in the last trading session, representing a 20.89% increase.

What is CAMP4 THERAPEUTICS CORPORATION (CAMP) current market capitalization?

CAMP4 THERAPEUTICS CORPORATION market cap is approximately 341.38 million.

What is CAMP4 THERAPEUTICS CORPORATION (CAMP) Earnings Per Share (EPS)?

The trailing EPS is -$2.31, and the forward EPS is -$0.79.

What is CAMP4 THERAPEUTICS CORPORATION (CAMP) EBITDA?

CAMP4 THERAPEUTICS CORPORATION EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -33.53 million.

Does CAMP4 THERAPEUTICS CORPORATION (CAMP) pay dividends?

No. CAMP4 THERAPEUTICS CORPORATION does not pay a dividend.

How did CAMP4 THERAPEUTICS CORPORATION (CAMP) perform in its most recent earnings report?

In the last report (June 30, 2026), CAMP4 THERAPEUTICS CORPORATION posted an EPS surprise of 8.33% and a revenue surprise of -5.87%.

What is CAMP4 THERAPEUTICS CORPORATION (CAMP) beta (volatility) score?

CAMP4 THERAPEUTICS CORPORATION has a beta of 0.034, indicating lower volatility than the overall market.